First Reported Case of Hemopericardium Related to Dabigatran Use Reversed by New Antidote Idarucizumab

Dabigatran, the first novel oral anticoagulant (NOAC) with a reversal agent, heralded a paradigm shift in the treatment of nonvalvular atrial fibrillation. The potential for life-threatening hemorrhagic events with the use of NOACs has been highly debated since the effectiveness of reversal agents s...

Full description

Saved in:
Bibliographic Details
Published in:Case reports in cardiology 2017-01, Vol.2017 (2017), p.1-3
Main Authors: Salciccioli, Louis, Meade, Matthew, Goulbourne, Clive, Cook, Joselle, Song, Steven, Lazar, Jason M.
Format: Article
Language:English
Subjects:
Anticoagulants
Blood
Cardiac arrhythmia
Case Report
Chemotherapy
Clinical trials
Drug dosages
Glycoproteins
Hemorrhage
Laboratories
Neutropenia
Patients
Pneumonia
Tomography
Ultrasonic imaging
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Dabigatran, the first novel oral anticoagulant (NOAC) with a reversal agent, heralded a paradigm shift in the treatment of nonvalvular atrial fibrillation. The potential for life-threatening hemorrhagic events with the use of NOACs has been highly debated since the effectiveness of reversal agents such as idarucizumab is based primarily on pharmacologic data. It is known that cancer patients are at an increased risk of bleeding with anticoagulation, though specific studies demonstrating the risks or efficacy of NOACs in this population are lacking. We provide the first report of hemopericardium resulting in multiorgan failure related to dabigatran use that was successfully reversed by idarucizumab in a man with prostate cancer on chemotherapy.
ISSN:2090-6404
2090-6412
DOI:10.1155/2017/6458636